Effect of tolvaptan on hyponatremia in a dog with syndrome of inappropriate secretion of antidiuretic hormone

J Vet Med Sci. 2023 Oct 17;85(10):1047-1051. doi: 10.1292/jvms.23-0243. Epub 2023 Aug 16.

Abstract

A 1-year-old spayed female Miniature Schnauzer had chronic hyponatremia, accompanied by polyuria and polydipsia. Blood tests and urinalysis revealed severe hyponatremia, low plasma osmolality with euvolemia, and increased sodium excretion in urine. Hypothyroidism and hypoadrenocorticism were ruled out as causes. These findings led to the diagnosis of syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Magnetic resonance imaging (MRI) showed dilation of the lateral ventricles, indicating severe hydrocephalus. Tolvaptan, a vasopressin V2 receptor antagonist commonly used in human SIADH, was administered along with water restriction. This treatment resulted in a consistent increase in plasma sodium levels without any adverse effects. This case report represents the first documented evidence of the therapeutic efficacy of tolvaptan in treating SIADH in a dog.

Keywords: congenital hydrocephalus; dog; syndrome of inappropriate secretion of antidiuretic hormone; tolvaptan.

Publication types

  • Case Reports

MeSH terms

  • Animals
  • Antidiuretic Hormone Receptor Antagonists / therapeutic use
  • Benzazepines / therapeutic use
  • Dog Diseases* / drug therapy
  • Dogs
  • Female
  • Humans
  • Hyponatremia* / drug therapy
  • Hyponatremia* / etiology
  • Hyponatremia* / veterinary
  • Inappropriate ADH Syndrome* / complications
  • Inappropriate ADH Syndrome* / drug therapy
  • Inappropriate ADH Syndrome* / veterinary
  • Sodium
  • Tolvaptan / therapeutic use
  • Vasopressins / therapeutic use

Substances

  • Tolvaptan
  • Antidiuretic Hormone Receptor Antagonists
  • Vasopressins
  • Sodium
  • Benzazepines